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ABSTRACT 
Gastric infections are mostly triggered by Helicobacter pylori (H. pylori), a fungus that colonizes the stomach mucosa of more than 50% of the i
nhabitants of the world. Chronic H. Pylori diseasewas associated with stomach diseases such as peptic ulcer, chronic gastritis and stomach aden
oc arcinoma. Current therapy for eradication relies on antibiotic-based therapies that are ineffective in about 20% of patients. Traditional 
method constraints optimize the creation of new techniques for fast, consistent and cost-effective H diagnosis. Infection with pylori. Wide-
ranging study has been carried out over the previous few centuries to create a type of gastro-retentive dosage (GRDF). This sort of dosage form 
can advance the delivery and efficiency of stomach-active medicines because the GRDF enables the medication to remain in the stomach for a 
sufficient time period. Various methods were used to develop effective GRDFs such as high-density systems, low-density systems, swelling and 
expansion systems, hydrodynamically balanced systems, superporous hydrogels,. However, there are both merits and demerits in these kinds 
of schemes. Intra-individual and inter-individual dissimilarities are obstacles to the growth of effective GRDFs in gastric physiology. Examples 
of these individual differences include gastric pH and gastric motility that have a notable effect on the moment of stomach retention and 
delivery of drugs. Some of these obstacles can be overcome by developing a novel mucoadhesive microsphere. The mucoadhesive microsphere 
is characterized by close contact of the MDF with the mucosal layer, thereby increasing the localized absorption of the drug. H2Receptor 
antagonists (H2RAs) have become first-line therapy for acid related peptic disease and GRDF especially designed for H2RAs and drugs against H. 
pylori, including specific targeting systems and leading to a marked development in the quality of life for a large number of patients. In this 
relationship, new formulations with improved absorption, improved bioavailability and improved acid-suppressing regimens are welcome 
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Introduction 
H. Pylori, a gram-negative microaerophilic spiral bacterium, 
were created in 1982 by Warren and Marshall as a significant 
cause organism for peptic ulcer1. Approximately half of the 
world's inhabitants are infected with this pathogen, but only 
a tiny percentage of infected inhabitants show clinical signs, 
mostly dependent on bacterial virulence dissimilarity and 
hostile factor. H. Pylori infection occurs in 90-100% of 
patients with duodenal ulcer and 60-90% of patients with 
stomach ulcer. The H has been shown by numerous 
researches. Pylori infection is associated with an enhanced 
danger of peptic ulcer disease of at least 3 to 4 folds and that 
of 10-15% H. Individuals infected with pylori will have the 
disease of peptic ulcer in their lifetime2. H. pylori is the major 
contributing organism of the unceasing gastritis 3, peptic 
ulcer4, B-cell MALT lymphomas5, gastric carcinoma6, and 
childhood malnutrition-associated carcinoma7. All of these 
are associated with an increase in epithelial cell apoptosis8. 
WHO has programmed H. pylori-associated gastric 
carcinoma as one of the three major causes of cancer-related 
deaths universal, around 0.5 million deaths each year. 
Chemotherapy of gastric cancer has deprived clinical 
efficacy; however, the abolition of H. pylori infection could 
possibly stop gastric carcinoma and other associated 
diseases. It is now well recognized that the maximum 
incidence of H. pylori infection is additional in children of 11-
16 years mainly for lower socioeconomic condition due to 
deprived level of hygiene9. The occurrence of H. pylori 
infection in India has been reported to be extremely high, 
ranging from 70% to 90% in patients with duodenal and 
peptic ulcer and 50% to 80% in patients with non-ulcer 
dyspepsia as well as fit asymptomatic adults10. A triple 
therapy containing 2 antibiotics and 1 proton inhibitor over 
a period of 2 weeks is optional universal for abolition of H. 
pylori. But deprived stability of antibiotics in acidic 
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environment and deprived permeation of antibiotics across 
the mucus layer cause incomplete abolition and systemic 
side effects leading to patient disobedience11,12.  Numerous 
study studies on gastro-retentive drug delivery systems such 
as floating formulations, mucoadhesive drug delivery system, 
pH-sensitive gel system were conducted in order to increase 
gastric residence and local drug concentration at H. pylori-
infected site. These studies indicated the advantage of 
targeting drug to the gastric mucosal layer by dropping the 
dose of antibiotic therapy as well as improved patient’s 
compliance. In this review, we recapitulate the existing 
information on colonization of H. pylori and gastroretentive 
mucoadhesive microsphere studies conducted in past few 
years, so as to utilize the information for future research on 
H. pylori abolition therapy. 
Colonization of H. pylori  
H. pylori are a motile pathogen which lives profound in the 
gastric mucus layer close to the epithelial cells. In common, 
after the entrance of any bacteria into the stomach, gastric 
acidity and peristaltic movement slow down the bond and 
migration of the bacteria in the gastric mucus layer. The 
incessantly secreted mucus from glands of the epithelial cell 
pushes bacteria toward the luminal surface, where the extra 
acidic environment delays the colonization and motility 
property of the pathogens 13-15. However, even in these 
aggressive conditions, H. pylori sticks to the mucus layer and 
penetrates deep in the mucus membrane close to the 
epithelial cells due to good motility of flagellae and various 
adhesions present on its surface as shown in Figure 1. Once 
the bacterium establishes the adhesion with the mucus layer, 
the enzyme urease secreted by H. pylori metabolizes gastric 
urea to produce Co2 and ammonia, which produces a 
surrounding coat of buffered acid. previous it was assumed 
that H. pylori usually colonizes in the mucus just close 
nearby to epithelial cell and do not penetrate the epithelial 
cells16 but one of the recent study showed the attack of H. 
pylori in the intercellular space of gastric epithelial cell17. 
Thus, migration of H. pylori in the gastric mucus layer is 
determined by various dangerous and aggressive factors. 
Urease and flagella are two most significant dangerous 
factors for successful migration of H. pylori15,18,19. Among 
aggressive factors, Lewis blood group antigens are most 
significant factors for mucosal adhesions of bacteria. Based 
on composition, Lewis antigen are of two types: type 1, 
mainly dispersed in the epithelium surface contain Lea, Leb 
and sialyl-Lea, while type 2 located deeper in the mucous/ 
parietal cell contain LeX, LeY and sialyl-LeX. It is also well 
recognized that Leb and LeX are major aggressive factors 
that are responsible for H. pylori adhesion to the gastric 
epithelial cell20. In addition to Lewis antigen, integrins are 
other factors for adhesion of H. pylori. Apart from lewis 
antigens, blood group antigen-binding adhesion (Bab A) 
protein21and Sialic acid-binding adhesion (Sab A) protein22 
are adhesion factors present on the outer membrane of H. 
pylori. Bab A and Sab A recognize hostile factors Leb and LeX 
respectively for adhesion on gastric epithelial cell 22,23. Sheu 
et al. (2003) 24 reported the expression of Leb antigen as a 
cause behind nearly 73% of H. pylori infection. Once H. pylori 
adheres to the epithelial cell, it produces a direct injurious 
effect, which is augmented by production and release of 
vacuolating cytotoxin (VacA) 25,26 
. 
 
Figure 1: Steps involved in colonization of H. pylori 
Present therapy and its limitations 
The treatment chart presently adopted as a first-line option 
includes a combination of a proton pump inhibitor, 
amoxicillin and clarithromycin or metronidazole/tinidazole, 
according to International Guidelines27,28. This therapy 
continues during 7 to 14 days, twice a day. Abolition rates of 
H. pylori treated with a 14-day 3 therapy reached only 70% 
in non-ulcer dyspepsia patients and 80% in patients with 
peptic ulcer27. In Europe, Asia and North America rates of 20 
to 45% have been reported29. This abolition rate is remote 
from the attractive rate to infectious diseases and from that 
proposed by the WHO28,30. The major limitation of the 
present therapy results from the lack of therapeutic 
compliance, due to the occurrence of side effects and the 
uneasiness resulting from the multiple doses31,32. These 
factors may lead to the expansion of antibiotic resistance32. 
Moreover, antimicrobial agents such as amoxicillin and 
clarithromycin are dishonored by gastric acid30. Therefore it 
is necessary to use higher doses, which is reflected in the 
increase of GIT side effects, namely diarrhea, nausea, 
vomiting, bloating and abdominal pain and as a result the 
discontinuation of the therapy32. Another important cause is 
the antibiotic resistance that H. pylori has been developing, 
for instance the resistance to metronidazole has reached 
around 40% in developed countries and exceeds 90% in 
developing countries33. The resistance to clarithromycin has 
also been increasing, reaching more than 20% in southern 
Europe29. The bacteria are sensitive to other antimicrobial 
drugs; nevertheless they cannot be used in acidic medium30. 
Not- withstanding, the antibiotic residence time in the 
stomach is inadequate to achieve significant concentrations 
capable of crossing the gastric mucosa and reaching the 
surface between the mucus gel layer and the epithelial cells, 
where the H. pylori resides. Although drug solutions reach 
the gastric luminal region, their absorption into deeper 
layers of the gastric mucosa is vulnerable by the mucous 
layer barrier34. In order to increase the efficacy of H. pylori 
abolition, different suggestions have been made, namely a 
bismuth-containing quadruple therapy, sequential and 
attendant treatment and the use of novel antibiotics, such as 
rifabutin35,36. However, these options may have to take into 
account that the difficulty of the treatment plan, including 
the switch middle in the sequential treatment and the large 
number of pills in attendant and BCQ therapy, may decrease 
therapeutic compliance. To overcome these limitations, 
novel effective therapies have been proposed: probiotics37,38, 
phytomedicine, gastroretentive systems, namely floating 
drug delivery systems39,40  and in a preventive approach, the 
attempt to develop an effective vaccine29. One of the leading 
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promising therapies that have newly emerged is based on 
the use of micro- or nanoparticles for direct contact with the 
H. pylori, through drug delivery techniques or mucoadhesive 
properties.  
Novel drug delivery approaches for H. pylori 
Literature review reveals that local use of antibiotics to 
gastric mucosa resulted in better abolition compared to 
systemically available antibiotic41. Hence, for successful 
abolition of H. pylori the DDS should sufficiently deliver the 
therapeutic agent in the close nearness of the gastric mucus 
membrane. In current years, various novel approaches are 
used for increasing the gastric residence time of the delivery 
system and local action of the drug in stomach. Different 
strategies utilized are: 
(i) Density-based approaches including a high density 
system and a low density system  
(ii) The floating drug delivery system,  
(iii) The mucoadhesive/bioadhesive system  
(iv) The swelling system for improving the gastric 
retention time of the system. 
(v) Incorporation of passage delaying food agents 
(vi) Ion exchange resins 
(vii) Osmotic regulated systems 
(viii) Hydrodynamically balanced systems 
(ix) Gas-generating systems 
(x) Raft-forming systems ect. 
Physiological consideration 
Over the past few decades, pharmaceutical study and 
formulation development scientists have documented the 
potential of site-specific ODDS. The stomach site has been 
recognized as a depot for CRDF. However, formulation 
scientists have to consider physiological variations such as 
gastric residence time, gastric emptying time and drug 
release from the dosage form. Once solid material (food 
and/or drug) is chewed and swallowed, the esophagus 
quickly transports it to the stomach. The stomach is mostly 
divided into two parts: the proximal stomach, consisting of 
the fundus and body and the distal stomach, consisting of the 
antrum (or pylorus). The proximal stomach serves as a food 
reservoir, whereas in the distal stomach the food is 
processed, forming chyme and proteins are partly broken 
down. The distal stomach (pylorus) acts as pump to help in 
GE. The rate of GE is prejudiced by both the volume of food 
and the composition of the gastric contents. However, the 
pattern of gastrointestinal motility varies significantly in 
both fasting and fed states, further influencing the GE time. 
The fasted state is characterized by an interdigestive series 
of electrical events which cycle both through the stomach 
and small intestine every 2-3 h42. This cycling event is 
termed the migrating myoelectric complex (MMC). The MMC 
is classified into 4 phases43 as enumerated below and as 
depicted in Fig. 2. In the case of the fed state, the GE time is 
slowed as the onset of the MMC is interrupted. For example, 
the feeding state results in a lag time (i.e. 30 min-4 h) prior 
to the onset of GE. 
 
Fig. 2. Motility pattern in GIT 
Composition of gastric mucus  
The stomach wall is composed of numerous distinct layers of 
tissue: outer mucosa, inner submucosa, muscularis externa 
and serosa. The mucosa or lining of the stomach is 
comprised of columnar epithelial tissue, lamina propria 
(composed of areolar connective tissue) and a thin layer of 
smooth muscle. The mucosal cells (goblet cells) exude mucus 
(a translucent and glutinous secretion) which coats the 
stomach lining and stops its destruction from the gastric 
juice43. The mean thickness of the mucosal layer varies from 
about 50 to 450 mm in humans. Mucus is a complex mixture 
and its composition varies depending upon the source and 
the pathological state of the human44,45 (Table 1).
 
Table 1 Composition of mucus44,45. 
Composition Percentage (%) 
Water 90-95% 
Mucin 5-10% 
Electrolyte 1% 
Others ((Enzyme, Nucleic acid, Lipid, Plasma protein, 
Secretory IgA, Bacteria and their decomposition products) 
4% 
 
Mucoadhesive microspheres  
Recent advances in polymer science and drug carrier 
technologies have promulgated the development of novel 
drug carriers such as mucoadhesive microspheres that have 
boosted the use of bioadhesion in the drug delivery46. 
Mucoadhesive microspheres include microparticles and 
microcapsules of 1 to 1000 μm in diameter consisting either 
completely of mucoadhesive polymer or having an outer 
coating with adhesive property47. Microspheres have the 
possible to be used for controlled as well as spatial drug 
delivery. Incorporating mucoadhesivenes to microspheres 
leads to competent absorption and enhanced bioavailability 
of drug. Precise targeting of drug to the absorption site is 
achieved by using homing devices (ligand) like plant lactin, 
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bacterial adhesion etc. on the surface of the microspheres. 
Mucoadhesive microspheres can be modified to stick to 
mucosal linings of GIT, thus offering the possibilities of 
localized as well as systemic absorption of drug in controlled 
manner48,49. 
Mechanism of mucoadhesion  
Usually, mucoadhesion occurs from the interactions between 
the drug and carrier molecules with different mucus 
membranes in two steps: the contact stage and the 
consolidation stage (Fig. 3) 50. However, the mechanism of 
mucoadhesion is highly complex and not yet fully 
understood. Different chemical interactions such as ionic 
bonds, covalent bonds, hydrogen bonds, Van der Waals 
forces and hydrophobic interactions are concerned in the 
mucoadhesion process that facilitates interactions of drug 
molecules across the interface. Several theories have been 
investigated to allow the understanding of mucoadhesion51. 
Electronic theory 
Adsorption theory 
Wetting theory 
Diffusion theory 
Fracture theory 
 
 
Fig. 3 The two stages in mucoadhesion 
Types of Mucoadhesive Polymers  
First generation mucoadhesive polymers  
It may be divided into 3 main sub-categories, namely: 
Anionic polymers, Cationic polymers and non-ionic 
polymers. Amongst these anionic and cationic polymers 
have been exhibits the greatest mucoadhesive strength52. 
Anionic polymers 
Anionic polymers are the most widely employed 
mucoadhesive polymers within pharmaceutical formulation 
due to their high mucoadhesive functionality and low 
toxicity. These include alginates, carrageenan, poly acrylic 
acid and its weakly cross-linked derivatives and sodium 
carboxymethylcellulose. PAA and NaCMC possess excellent 
mucoadhesive characteristics due to the formation of strong 
hydrogen bonding interactions with mucin53. Polycarbophil 
and carbomer (Carbopol, PAA derivatives have been studied 
extensively as mucoadhesive platforms for drug delivery to 
the GI tract54,55. Carbomers are cross-linked with allyl 
sucrose or allylpentaerythritol whereas polycarbophil 
polymers are cross-linked with divinyl glycol. Both 
compounds have the same acrylic backbone but vary in their 
cross-link density that is often tailored to suit 
pharmaceutical or cosmetic performance.  
Cationic polymers  
Chitosan is a cationic polysaccharide the most abundant 
polysaccharide in the planet, next to cellulose56. The most 
explored mucoadhesive polymers, chitosan is gaining 
increasing importance due to its good biocompatibility, 
biodegradability and due to their favourable 
toxicological57.The linearity of chitosan molecules also 
ensures sufficient chain flexibility for interpenetration58. 
Chitosan may provide improved drug delivery via 
mucoadhesive mechanism; it has also been shown to 
improve drug absorption via the paracellular route through 
neutralization of fixed anionic sites within the tight junctions 
between mucosal cells59,60. 
Novel second-generation mucoadhesives polymers. 
Second generation includes lectins and thiolated polymers.  
Lectin is normally defined as proteins or glycoprotein 
complexes of non-immune origin that are able to bind sugars 
selectively in a non-covalent manner61. Lectins are capable 
of attaching themselves to carbohydrates on the mucus or 
epithelial cell surface and have been extensively studied, 
especially for drug-targeting applications62,63. These second-
generation bioadhesives not only provide for cellular 
binding, but also for subsequent endo- and transcytosis.  
Thiolated polymers, also designated thiomers, are 
hydrophilic macromolecules exhibiting free thiol groups on 
the polymeric backbone. Due to these functional groups, 
various features of polyacrylates and cellulose derivatives 
were strongly improved64. The presence of thiol groups in 
the polymer allows the formation of stable covalents bonds 
with cysteine-rich subdomains of mucus glycoproteins 
leading to increased residence time and improved 
bioavailability65. Other advantageous mucoadhesive 
properties of thiolated polymers include improved tensile 
strength, rapid swelling and water uptake behavior. .e.g-
various thiolated polymers include chitosan-thioglycolic 
acid,chitosan-thioethylamidine, alginate-cysteine. 
Methods of Preparation of Mucoadhesive 
Microspheres 
 Emulsion cross-linking method. 
 Single emulsion techniques. 
 Ionotropic gelation.  
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 Phase inversion method.  
 Spray drying and spray congealing method.  
 Solvent removal method.  
 Hot melt method. 
 Polymerization 
Conclusion  
In gastric ulcers caused by H. pylori, the treatment requires 
high concentration of antibacterial agents like 
clarithromycin or metronidazole or amoxicillin in stomach 
and absorption through gastric mucosa. However, presently 
available conventional drug deliveries of these drugs fail to 
achieve the same. A lot of extraordinary novel drug delivery 
approaches making use of buoyancy and bioadhesion to 
increase the gastro-retention time have been developed for 
the treatment of H. pylori infection. Among many novel 
delivery systems investigated so far for gastric delivery of 
drugs for H. pylori, the mucoadhesive microspheres showed 
the great potential for the selectively delivering the drug at 
infection site. By modifying the surface groups present on 
mucoadhesive polymers, increased mobility of nanoparticles 
in the gastric mucus can be obtained for better abolition of 
H. pylori. These systems are connected with major problems 
like stability on prolonged storage, consistency of drug 
entrapment and drug release and industrial scale up.
 
Table 2: An over view of cited Mucoadhesive Microspheres delivery approaches for H. Pylori eradication 
Polymers used Drug Mechanism Salient features Ref 
Ethyl cellulose and 
carbomer 937 
Amoxicillin Microspheres Protection of drug in stomach 66 
chitosan Amoxicillin Microspheres Increased gastric retention, gastric stability of drug and 
better H. pylori clearance effect than amoxicillin powder 
67 
Carbopol-934P Amoxicillin Microspheres 80% mucoadhesion after 1 h, Better H. pylori clearance 
effect than amoxicillin powder 
68 
CAB and cholestyamine AHA Microspheres Increase gastric retention time up to 12 h 69 
Polycarbonate AHA Microspheres Increase gastric retention time up to 12 h 70 
Modified gelatin Amoxicillin Microspheres Increase mucoadhesion 71 
Gelatin/Acrypol 934P LEVOFLOXACIN Microspheres Increase mucoadhesion 72 
carbopol 974P, 
Eudragit RS 100 
Clarithromycin Microspheres Increase gastric retention time up to 12 h 73 
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